SCHEMBL2723077

SCHEMBL2723077

C#CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)/C=N\Oc3csc(N)n3)[C@H]2SC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 7/20 0.47
▸ MAPT P10636 4/20 0.47
▸ ABCC4 O15439 3/20 0.47
▸ CNR1 P21554 1/20 0.47
▸ CTDSP1 Q9GZU7 1/20 0.47
▸ HPGD P15428 1/20 0.46
▸ APEX1 P27695 3/20 0.45
▸ APAF1 O14727 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ L3MBTL1 Q9Y468 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ PLCG1 P19174 1/20 0.45
▸ ABCC2 Q92887 1/20 0.45
▸ SIRT5 Q9NXA8 1/20 0.45
▸ PSMD14 O00487 1/20 0.45
▸ MMP2 P08253 1/20 0.45
▸ NR1I2 O75469 5/20 0.45
▸ HTR2C P28335 1/20 0.45
▸ PPARG P37231 2/20 0.43
▸ SLC22A6 Q4U2R8 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3294983 0.86 TDP1 (0.64) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL1902817 0.86 TDP1 (0.64) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL2724710 0.77 TDP1 (0.73) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL10528776 0.76 NR1I2 (0.75) TDP1MAPTABCC4APEX1APAF1
SCHEMBL10528758 0.76 NR1I2 (0.75) TDP1MAPTABCC4APEX1APAF1
SCHEMBL10528838 0.75 TDP1 (0.75) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL9703691 0.75 NR1I2 (0.61) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL9703703 0.75 NR1I2 (0.61) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL10528849 0.75 TDP1 (0.75) TDP1MAPTABCC4CNR1CTDSP1
SCHEMBL4809163 0.74 NR1I2 (0.50) TDP1MAPTABCC4CNR1CTDSP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2012078121-A2 SOLID ORAL DOSAGE FORM COMPRISING CEFDINIR BILGIC MAHMUT (TR) 2012-06-14 — — WO disclosed
WO-2012060787-A1 ORAL DOSAGE FORMS COMPRISING CEFDINIR AND CARBOXYMETHYL CELLULOSE CALCIUM BILGIC MAHMUT (TR) 2012-05-10 — — WO disclosed
WO-2012060792-A1 PHARMACEUTICAL COMPOSITIONS COMPRISING MINIMUM 6 % OF DISINTEGRANTS BY WEIGHT BILGIC MAHMUT (TR) 2012-05-10 — — WO disclosed
WO-2012060791-A2 PRODUCTION METHOD FOR PHARMACEUTICAL COMPOSITIONS COMPRISING CEFDINIR BILGIC MAHMUT (TR) 2012-05-10 — — WO disclosed
Send feedback